[{"data":1,"prerenderedAt":173},["ShallowReactive",2],{"drug-argatroban":3},{"id":4,"schemaVersion":5,"name":6,"category":9,"class":10,"brands":13,"synonyms":16,"formulations":17,"regimens":31,"contraindications":76,"warnings":86,"renal":87,"monitoring":88,"interactions":89,"review":90,"examples":93,"atc":106,"iran":108,"usApproval":120,"links":126,"populations":139},"argatroban",1,{"fa":7,"en":8},"آرگاتروبان","Argatroban","blood",{"fa":11,"en":12},"مهارکننده مستقیم ترومبین","Direct thrombin inhibitor",[14],{"name":8,"market":15},"US",[4,7],[18],{"id":19,"form":20,"route":21,"label":22,"concentration":23,"markets":26,"refs":27},"vial-1-mcg","injection","iv","125 mg\u002F125 mL ready-to-use (1 mg\u002FmL = 1000 mcg\u002FmL)",{"amount":24,"unit":25,"perVolumeMl":5},1000,"mcg",[15],[28],{"source":29,"section":30},"fda-argatroban","3",[32,56],{"id":33,"disease":33,"label":34,"population":37,"type":41,"unit":25,"dose":42,"refs":44,"notes":47},"hit",{"fa":35,"en":36},"HIT (با یا بدون ترومبوز) — شروع ۲ mcg\u002Fkg\u002Fدقیقه (حداکثر ۱۰)","HIT (with or without thrombosis) — start 2 mcg\u002Fkg\u002Fmin (max 10)",{"minAge":38},{"value":39,"unit":40},18,"year","infusion",{"perKgPerMin":43},2,[45],{"source":29,"section":46},"2.2",[48],{"text":49,"refs":52},{"fa":50,"en":51},"هپارین قطع و aPTT پایه گرفته شود. تنظیم تا aPTT ۱٫۵ تا ۳ برابر پایه (نه بیش از ۱۰۰ ثانیه)؛ حداکثر ۱۰ mcg\u002Fkg\u002Fدقیقه. نارسایی متوسط\u002Fشدید کبد: دوز کمتر.","Stop heparin and get a baseline aPTT. Adjust to aPTT 1.5–3× baseline (not >100 s); max 10 mcg\u002Fkg\u002Fmin. Moderate\u002Fsevere hepatic impairment: lower dose.",[53,54],{"source":29,"section":46},{"source":29,"section":55},"2.4",{"id":57,"disease":58,"label":59,"population":62,"type":41,"unit":25,"dose":64,"refs":66,"notes":69},"pci","acute-coronary-syndrome",{"fa":60,"en":61},"PCI در HIT — انفوزیون ۲۵ mcg\u002Fkg\u002Fدقیقه (به‌اضافه بولوس ۳۵۰ mcg\u002Fkg)","PCI in HIT — infusion 25 mcg\u002Fkg\u002Fmin (plus a 350 mcg\u002Fkg bolus)",{"minAge":63},{"value":39,"unit":40},{"perKgPerMin":65},25,[67],{"source":29,"section":68},"2.3",[70],{"text":71,"refs":74},{"fa":72,"en":73},"بولوس ۳۵۰ mcg\u002Fkg در ۳ تا ۵ دقیقه؛ ACT ۵ تا ۱۰ دقیقه بعد؛ ادامه PCI اگر ACT بالای ۳۰۰ ثانیه.","Bolus 350 mcg\u002Fkg over 3–5 min; check ACT 5–10 min later; proceed if ACT >300 s.",[75],{"source":29,"section":68},[77],{"id":78,"severity":79,"text":80,"refs":83},"ci","block",{"fa":81,"en":82},"خونریزی شدید؛ سابقه حساسیت به آرگاتروبان.","Major bleeding; history of hypersensitivity to argatroban.",[84],{"source":29,"section":85},"4",[],[],[],[],{"status":91,"reviewer":92,"date":92},"unverified",null,[94,101],{"regimen":33,"formulation":19,"input":95,"expect":98},{"ageYears":96,"weightKg":97},60,70,{"perMin":99,"mlPerHour":100},140,8.4,{"regimen":57,"formulation":19,"input":102,"expect":103},{"ageYears":96,"weightKg":97},{"perMin":104,"mlPerHour":105},1750,105,[107],"B01AE03",{"status":109,"forms":110,"refs":115},"registered",[111],{"code":112,"en":113,"fa":114},"22330","ARGATROBAN 250MG\u002F2.5ML VIAL","ویال آرگاتروبان ۲۵۰ میلی‌گرم \u002F ۲٫۵ میلی‌لیتر",[116],{"source":117,"section":118,"url":119},"darooyab-generic","G-1534\u002FArgatroban","https:\u002F\u002Fwww.darooyab.ir\u002FG-1534\u002FArgatroban",{"kind":121,"refs":122,"id":125},"NDA",[123],{"source":29,"section":124},"SPL approval \u002F marketing category","NDA022485",[127,130,134,137],{"kind":128,"url":129,"label":125},"fda","https:\u002F\u002Fwww.accessdata.fda.gov\u002Fscripts\u002Fcder\u002Fdaf\u002Findex.cfm?event=overview.process&ApplNo=022485",{"kind":131,"url":132,"label":133},"dailymed","https:\u002F\u002Fdailymed.nlm.nih.gov\u002Fdailymed\u002FdrugInfo.cfm?setid=514ad15b-d060-9d65-e063-6294a90a6188","FDA Argatroban",{"kind":135,"url":136,"label":107},"who-atc","https:\u002F\u002Fatcddd.fhi.no\u002Fatc_ddd_index\u002F?code=B01AE03",{"kind":138,"url":119,"label":8},"darooyab",{"pregnancy":140,"lactation":149,"pediatric":157,"geriatric":165},{"level":141,"text":142,"quote":145,"refs":146},"caution",{"fa":143,"en":144},"برچسب خطر مشخصی برای بارداری ذکر نکرده یا داده کافی ندارد؛ فقط در صورت لزوم و با نظر پزشک.","Label states no clear risk or has limited data; use only if needed, under medical advice.","Risk Summary Limited data from published literature and postmarketing reports do not suggest an association between argatroban and adverse fetal outcomes.",[147],{"source":29,"section":148},"8.1",{"level":141,"text":150,"quote":153,"refs":154},{"fa":151,"en":152},"برچسب: در شیردهی با احتیاط؛ متن برچسب را ببینید.","Label: use with caution while breastfeeding; see the label text.","There are no data on the presence of argatroban in human milk, or its effects on milk production.",[155],{"source":29,"section":156},"8.2",{"level":141,"text":158,"quote":161,"refs":162},{"fa":159,"en":160},"برچسب برای کودکان شرط، محدودیت سنی یا نکته دارد؛ جمله برچسب در زیر آمده است.","The label has conditions, age limits or notes for children; the label sentence is quoted below.","Safety and effectiveness have not been established in pediatric patients.",[163],{"source":29,"section":164},"8.4",{"level":141,"text":166,"quote":169,"refs":170},{"fa":167,"en":168},"برچسب: در سالمندان با احتیاط و معمولاً از دوز پایین شروع شود.","Label: use with caution in older adults, usually starting at the low end of the dose range.","The safety analysis did suggest that older patients tended to have an increased risk of events compared to younger patients; however, older patients had increased underlying conditions, which may predispose them to adverse reactions.",[171],{"source":29,"section":172},"8.5",1792156162723]